In order to keep the mass of catalysis constant, some catalyst (about 2 mg) were added.
Fentanyl 300 μg and rocuronium 20 mg were added during surgery.
Valproic acid 800 mg and levetiracetam 500 mg were added for anticonvulsive therapy.
Promoting elements, Ca and Mg, were added to SBA-15 support prior to the active phase, Cu (2 wt%) and Ni (7 wt%).
Compound B (10 mg, 30 × 10−3 mmol) was dissolved in 3 mL of acetone (0.1 M); prenyl bromide (2 mL) and K2CO3 (3 mg) were added successively.
EDC (4.25 mg) and sulfo-NHS linker (6.4 mg) were added to the particle-MES solution and incubated for 15 min at room temperature.
NHS (260 mg) and N,N-dicyclohexylcarbodiimide (470 mg) were added, and the mixture was reacted overnight at room temperature in the dark.
Siloxane-GNPs (50 mg) were added into 10 ml deionized water and stirred for 24 h at room temperature to hydrolyze the alkoxysilane into Si-OH.
MWCNTs (4.0 mg) were added to an aqueous suspension of GO (24 mL, 0.5 mg mL−1) under stirring and sonication.
Briefly, the PLGA (100 mg) was dissolved in DCM (5 ml); and then DCC (5 mg) and NHS (2.5 mg) were added under magnetic stirring.
Samples of one 1 mg were added to 2 ml of deionised water (18.2 MΩ cm), 3 ml of nitric acid (Merck, 65% Suprapur®) and 2 ml of hydrogen peroxide (Merck, 30% Suprapur®) as oxidiser.
